1	Metabolic Activity of Human Chorionic Gonadotropin (hCG) on Glycemia and
2	Leptinemia in Experimental Animals Fed a Cafeteria Diet
3	
4	Daniel Oscar Belluscio, MD. The Oral hCG Research Center. Buenos Aires, Argentina.
5	Nestor Lago, MD. Department of Pathology, UBA. Buenos Aires, Argentina. Ezequiel
6	Klimovsky MD. QUID LATAM Consulting. Buenos Aires, Argentina. Maria Elsa
7	Berdeal, MD. The Oral hCG Research Center. Buenos Aires, Argentina. Andrea
8	Federico, BS. QUID LATAM Consulting. Buenos Aires, Argentina.
9	
10	Corresponding author: Daniel Oscar Belluscio, MD. The Oral hCG Research Center.
11	Guido 1953 Apt 6 "14", ZIP code 1119. Buenos Aires, Argentina. Phone number: +54 11
12	4804 9784. Fax: +54 11 4804 9784. E-mail: <u>hcgobesity@fibertel.com.ar</u>
13	

Running title: hCG Affects Glycemia and Leptinemia in Animals

15 ABSTRACT

Objectives: To elucidate the relationship of hCG administration to glycemia, Non 16 Esterified Fatty Acids (NEFA), leptin and adiponectin levels on experimental animals 17 previously submitted to a cafeteria diet, and then to a Low Calorie Diet (LCD). Design: 18 Forty-one rats were selected (21 females, 20 males) and divided into seven (0-6) groups. 19 Animals from groups 1 to 6 were fed a "cafeteria diet" with a mean energy content of 20 10% protein, 30% carbohydrate and 60% fat. Animals from group 0 were fed the 21 standard laboratory diet. After the fattening period, animals from groups 1 to 6 were 22 submitted to a restricted diet consisting of one-third the average daily intake for rats. hCG 23 was administered for five weeks according to a specific protocol. The effects of hCG 24 treatment were evaluated using analysis of variance (ANOVA). Results: These 25 26 assessments were compared: (1) glycemia, adiponectins, leptins and non-esterified fatty acids (NEFA); (2) weight; (3) formulation effect; and (4) dose effect. Differences in 27 leptins were observed between the Control group and Injectable A (p=0.026), Intrarectal 28 29 Suspension A (p=0.20), Intrarectal Suspension B (p<0.001), and Intrarectal Suspension C (p < 0001) groups. In all cases, the average values were higher for the control group. 30 Significant differences were found in the groups treated with Injectable B, Intrarectal 31 Suspension B (p=0.025) and Intrarectal Suspension C (p=0.037). Groups receiving 32 Intrarectal Suspension B or C showed significantly lower mean leptin values. Differences 33 in glycemia were detected between the Control group and Intrarectal Suspension A 34 (p=0.021) and Intrarectal Suspension B (p=0.020) groups. Groups treated with Intrarectal 35 Suspension A or B showed lower mean blood glucose values. Conclusions: Results show 36 37 the activity of hCG (both urinary and recombinant) on glycemia and leptins levels in

experimental animals in different formulations, but specifically when administered
intrarectal. hCG administration significantly decreased blood sugar and leptin levels,
whereas adiponectins were only relatively sensitive to hCG treatment.

Keywords: Human chorionic gonadotropin (hCG); Leptins; Glycemia; Adiponectin.

42 INTRODUCTION

Human chorionic gonadotropin (hCG) was discovered in 1927 by Ascheim and Zondek 43 in the urine of pregnant women and was used for the treatment of conditions such as 44 infertility, cryptorchidism, and obesity $\frac{1-3}{2}$. Several extragonadal therapeutic actions have 45 been attributed to hCG, including (but not limited to) Kaposi sarcoma, glaucoma and 46 BPH (Benign Prostatic hypertrophy). One of the most controversial indications was its 47 use in the management of obesity, until a series of double blind studies conducted in 48 humans concluded that weight loss under hCG was no better than placebo. The standard 49 administration route was intramuscular. Its efficacy in obesity treatment was debated for 50 years until some studies found it was not useful for treating this condition $\frac{4-8}{2}$. In 1987, 51 Vogt and Belluscio published a study concluding the hCG protocol originally designed 52 by Simeons $\frac{3}{2}$ for obesity treatment was a suitable and safe approach to manage this 53 condition $\frac{9}{2}$. The authors also reasserted the role of the hypothalamus as a possible 54 intermediate organ for the lipolytic action of hCG $\frac{9}{2}$. 55

In 1999, Belluscio et al. worked on a modification of the hCG administration route as a strategy to modify its biological activity. They investigated the sublingual route, proposed a change in the administered dose, and in a double-blind study demonstrated the pharmacological activity of hCG in the reduction of adipose tissue total mass in volunteer subjects ¹⁰11.

Leptin was discovered in rats in 1994. Subsequently, the human Ob gene was located on chromosome 7. It is a cytokine that plays a key role in the regulation of energy balance. It is believed to act as a lipostate: when the amount of fat stored in adipocytes increases, leptin is released into the bloodstream and results in a negative feedback signal that acts 65 on the hypothalamus to inhibit appetite. When adipose tissue mass increases beyond the point of equilibrium, the synthesis and secretion of leptin increases. This, in turn, 66 stimulates several compensatory effects in the hypothalamus such as: anorectic peptide 67 production and suppression of orexigenics, increase of energy expenditure, increase of 68 basal metabolic rate and body temperature, and modification of the hormonal balance 69 point, thereby reducing lipogenesis and increasing lipolysis $\frac{12-19}{2}$. The regulation of leptin 70 secretion is associated with variations in body mass and insulin-stimulating effects. 71 However, many obese people have high serum concentrations of leptin or resistance to it, 72 indicating that other molecules such as ghrelin, serotonin, cholecystokinin and 73 neuropeptide Y also have an effect on satiety and contribute to body weight regulation $\frac{20}{2}$ 74 $\frac{25}{25}$. The molecular basis of leptin resistance is poorly understood; although the most 75 76 accepted hypothesis is its inability to cross the blood brain barrier or the result of defects in the leptin receptor $\frac{26}{2}$. 77

Adiponectin is a peptidic hormone abundantly expressed in mature adipocytes that circulate in high concentrations in plasma. Adiponectin expression decreases in all processes related to inflammation and insulin resistance such as obesity and diabetes mellitus. Plasma adiponectin decreases before the onset of obesity and insulin resistance in primates, suggesting that hypoadiponectinemia contributes to the pathogenesis of these diseases. Adiponectin levels increase when insulin sensitivity improves, either due to the reduction in body weight or to treatment with insulin sensitizing drugs ²⁷.

The purpose of this study was to determine by plasma biochemistry analysis the metabolic activity of different hCG formulations, either urinary or recombinant, as well

as its relationship to glucose, NEFA, adiponectin and leptin metabolism, and to assess its safety (particularly gonadal) through histological observations of target organs.

89

90 SUBJECTS AND METHODS

91 The study was conducted between December 12, 2008 and June 15, 2009 at the BIO FUCAL S.A. Center located at Acceso Norte km. 42.5, Del Viso, Buenos Aires, 92 Argentina, and sponsored by Daniel Belluscio MD. Forty-one rats (Rattus norvegicus, 93 Sprague Dawley strain) were selected comprised of 21 females and 20 males and divided 94 in seven (0-6) groups. Animals in groups 1 to 6 were fed a hypercaloric and highly 95 palatable cafeteria diet $\frac{28}{2}$, in contrast to animals from group 0, which continued with the 96 standard laboratory diet. The amount of food provided with this diet was "ad libitum" and 97 extended from December 12, 2008 (day 0 of treatment) to January 27, 2009. After the 98 99 fattening period, animals in groups 1 to 6 were subjected to a restricted diet consisting of one-third of the average daily intake of balanced food for rats, calculated separately for 100 both males and females. 101

102 hCG administration lasting five weeks was performed according to the following 103 protocol. Group 0 received no medication or diet and continued with the standard diet 104 throughout the course of the study. Group 1 was submitted to a hypocaloric diet without 105 hCG administration. Group 2 was submitted to a hypocaloric diet and received 125 106 International Units (IU) of hCG (urinary, Massone Laboratories, Buenos Aires, Argentina) dissolved in normal saline (NaCl 0.9%), administered intramuscularly and 107 daily, including Sundays (Injectable A). Group 3 was submitted to a hypocaloric diet and 108 109 received 125 IU of r-hCG (recombinant, Ovidrel®, Serono Laboratories, Buenos Aires, 110 Argentina) dissolved in normal saline (0.9% NaCl), administered intramuscularly and 111 daily, including Sundays (Injectable B). Group 4 was submitted to a hypocaloric diet and received 300 IU of hCG (urinary, Massone Laboratories, Argentina) in intrarectal 112 113 emulsion containing 8 mg/ml of cyclodextrin (Laboratory Roquette Freres, Lestrem, France) as enhancer, daily, including Sundays (Intrarectal Suspension A). Group 5 was 114 submitted to a hypocaloric diet and received 300 IU of hCG (urinary, Massone 115 Laboratories, Argentina) in intrarectal emulsion containing 16 mg/ml of cyclodextrin 116 (Laboratory Roquette Freres, France) as enhancer, daily, including Sundays (Intrarectal 117 suspension B). Group 6 was submitted to a hypocaloric diet and received 300 IU of r-118 hCG (recombinant, Ovidrel®, Serono Laboratories) as intrarectal emulsion containing 8 119 mg/ml of cyclodextrin (Laboratory Roquette Freres, France) as enhancer, daily, including 120 121 Sundays (Intrarectal Suspension C).

Injections were administered using 1 ml syringes and 16 x 5needles to the rear limbs between the semimembranosus and semitendinosus muscles, alternating one member per day. For intrarectal administration of the suspensions, the same syringes were used attached to an oesophageal probe for oral administration. The emulsion was deposited over the entire rectal surface, proximal to distal, keeping the anus closed for 1 minute. Both suspensions and injections were renewed every week and kept refrigerated at all times to ensure their biological activity.

129 Observations were systematically recorded on each treated animal once a day throughout

the duration of the trial. Body weight was assessed on days 0, 3, 6, 14, 21, 25, 33, 39

131 (beginning of the treatment), 46, 53, 63, 77 and 82. The following serological

determinations were assessed in each group at both baseline (day 39) and on the final day

133 (82), pre- and post- treatment, respectively: Glycemia (g/L) (Colorimetric end-point

- technique Autoanalyzer Hitachi 902 Wiener); adiponectin (ng/mL) (Rat adiponectin ELISA
- 135 kit-ELISA manual- Catalog N° K4903-100-Lot40203-Biovision Incorporated); leptin
- 136 (ng/mL) (Mouse Leptin-Quantikine Immunoassay-ELISA-Lot 259828-Catalog Nr.
- 137 MOBOO R&D Systems) and NEFA (mEq/L) (Mouse Non-ester Fatty Acid (NEFA)
- 138 ELISA Kit Product No.: CSB-E13618m-CUSABIO BIOTECH Co). Regarding the
- safety of hCG, histological evaluation of a general necropsy was performed. The
- 140 following organs and tissues were removed to perform the pertinent histopathological
- 141 studies: brain (half in buffered formaldehyde at 5% and half-frozen at -20° C), ovaries
- 142 (formaldehyde 5%) and testicles (5% formalin).

143 Statistical methodology

The effects of hCG treatment were evaluated using analysis of variance (ANOVA). The Kolmogorov-Smirnov test was also used to assess normality of distributions. Nonparametric analysis of variance was used to compare weights between treatments at the beginning and end of treatment. Descriptive analysis of adverse events was performed. SPSS® software V. 11.5 (Cary, IN, USA) was used to assess the determinations.

- 150
- 151 **RESULTS**

152 We compared basal and final determinations as follows.

153 General

154 Basal determinations

Figures 1 A-D show baseline results (before treatment) in the seven groups. To estimate their homogeneity, values were compared among the six groups submitted to high-calorie diets. No significant differences were found between groups: leptin (Fig. 1A), p=0.056; glycemia (Fig. 1B), p=0.291; adiponectin (Fig. 1C), p=0.364; and fatty acids (Fig. 1D), p=0.722.

160 Final determinations

Figures 2 A-D show final results (post treatment) in the seven groups. No significant 161 differences were observed in adiponectin (F=2,130, p=0.076) (Fig. 2C) or fatty acids 162 (F=1.056, p=0.408) (Fig. 2D), but statistically significant differences were observed in 163 leptin (F=7,066, p < 0.001) (Fig. 2A) and glucose (F=3,012, p = 0.018) (Fig. 2B). 164 Differences in leptin were observed between the Control group and the following groups: 165 Injectable A (p=0.026), Intrarectal Suspension A (p=0.20), Intrarectal Suspension B 166 (p < 0.001) and Intrarectal Suspension C (p < 0.001). In all cases, the average values were 167 higher for the Control group. Significant differences were also found in the group treated 168 with Injectable B and in the Intrarectal Suspension B (p=0.025) and Intrarectal 169 Suspension C (p=0.037) groups. Groups receiving Intrarectal Suspension B or C showed 170 171 significantly lower mean leptin values. Differences in glycemia were detected between 172 the Control group and the Intrarectal Suspension A (p=0.021) and Intrarectal Suspension 173 B (p=0.020) groups. Groups treated with Intrarectal Suspension A or B showed lower 174 mean blood glucose values.

175 **Treatment effect**

Differences were first assessed between the Control group (Group 0), the group that was
submitted to the hypocaloric diet (Group 1), and groups treated with hCG (Groups 2-6)
(treatment effect).

179 *Leptin*

Significant differences were found in leptins among the treatments groups (F=9,694, p<0.001). The average value in the Control group was 3.05, 1.92 in the group treated only with hypocaloric diet, and 1.12 in groups treated with hCG. The most significant differences were found between the Control group and groups treated with hCG (p<0,001), while no significant differences were found between the two groups that did not receive hCG.

186 *Glycemia*

187 Significant differences were also observed in plasmatic glucose final values (F=8,099, 188 p=0,001). The average value in the Control group was 1.78, 1.23 in the group treated 189 with hypocaloric diet, and 1.15 in the groups treated with hCG. This difference is 190 significant when comparing the Control group to the groups treated with hCG (p=0,001). Even though adiponectin plasmatic results were higher in the groups treated with hCG, 191 192 differences were not statistically significant (F=1,388, p=0.262). The average value in the Control group was 2.69, 4.12 in the group treated with hypocaloric diet, and 5.80 in the 193 groups treated with hCG. Statistically significant differences were not found in fatty acids 194 (F=0.763, p=0.473). The average value for the Control group was 0.97, 0.85 in the 195 hypocaloric diet group, and 0.90 in the groups treated with hCG. 196

Dose effect

To assess the effect of the administered dose, groups were matched as follows: Control
with standard diet, Control with hypocaloric diet, Injection A/Intrarectal Suspension A,
Injectable B / Intrarectal Suspension C, Intrarectal Suspension B.

201 *Leptin*

Significant differences in leptin were observed between the groups (Brown-Forsythe 202 203 5.473; p=0.009). The highest average values were recorded in the group that received the standard diet (3.05). Values were lower (1.92) in the group treated with hypocaloric diet, 204 and even lower in the groups receiving hCG. Among those groups, the lowest mean 205 values were recorded in animals receiving Intrarectal Suspension B. Differences were 206 significant between the Control group and the groups receiving Injectable A/Intrarectal 207 Suspension A (1.28, p=0.010), groups that received Injectable B/ Intrarectal Suspension 208 C (1.30, p=0.012), and groups that received Intrarectal Suspension B (0.47, p<0.001). 209

210 Glycemia

211 Significant differences were observed in blood glucose between groups (F=4,078, p=0.008). Animals from the Control group showed higher average blood glucose values 212 (1.78). A reduction in average values was observed in the group treated with hypocaloric 213 214 diet (1.23) and in all subjects receiving hCG. When comparing animals under treatment, the lowest mean average values were observed in those receiving Intrarectal Suspension 215 B (0.90). Significant differences were observed between the Control group and the group 216 receiving Injectable A/Intrarectal Suspension A (1.05, p=0.016), the group receiving 217 Injectable B/Intrarectal Suspension C (1.05, p=0.018), and the group receiving Intrarectal 218 Suspension B (p=0.009). 219

To estimate the effect of the administered formulation, groups were matched and analyzed as follows: Control with standard diet, Control with hypocaloric diet, subjects with Injectable A/Intrarectal Suspension, A/Intrarectal Suspension B, and subjects with Injectable B/Intrarectal Suspension C.

225 *Leptins*

226 Significant differences in leptin levels were observed between the groups (Brown-Forsythe 4978; p=0.020). The highest average values (3.05) were observed in the Control 227 group with standard diet. Values were lower (1.92) in the Control group with hypocaloric 228 229 diet and in the groups receiving hCG. When comparing groups, the lowest mean values (1.01) were observed in animals receiving Injectable A/Intrarectal Suspension 230 A/Intrarectal Suspension B. Statistically significant differences were found when 231 232 comparing the Control group with standard diet and animals receiving Injectable 233 A/Intrarectal Suspension A/Intrarectal Suspension B (p=0.001) and Injectable 234 B/Intrarectal Suspension C (1.30, *p*=0.009).

235 Glycemia

Significant differences were observed when comparing blood glucose levels between the groups (F=5.307, p=0.004). The highest average values (1.78) were detected in the Control group that received the standard diet, and values decreased in the Control group treated with the hypocaloric diet (1.23) and in groups receiving hCG (1.00 and 1.05, respectively). Differences were significant between the Control group with the standard diet and the groups receiving Injectable A/Intrarectal Suspension A/Intrarectal Suspension B (p=0.003) and Injectable B/Intrarectal Suspension C (p=0.010).

243 Pharmaceutical formulation effect

To estimate the different effects of the pharmaceuticals formulations, groups were split as follows: Control group with standard diet, Control group with hypocaloric diet, a group with Injectable A/B and a group with Intrarectal suspension A/B/C.

247 *Leptin*

248 Significant differences were observed in leptins between groups (Brown-Forsythe 7.398; 249 p=0.008). The highest average values (3.05) were recorded in the Control group with the 250 standard diet. In the Control group with the hypocaloric diet, the observed value (1.92) 251 was decreased and further reductions were observed in the groups receiving hCG. Among 252 the groups receiving treatment, lower average values (0.75) were found in the intrarectal 253 suspension A/B/C groups. Differences were significant between the Control group with 254 standard diet, the group receiving Injectable A/B (1.72, p=0.041), and the group receiving 255 Intrarectal suspension A/B/C (p <0.001). Differences were also significant between the groups with the hypocaloric diet and the Intrarectal suspension group (p=0.040), and the 256 257 Injectable and Intrarectal suspension groups (p=0.034).

258 Glycemia

Significant differences were observed in blood glucose levels among the groups (Brown-Forsythe F=5,667, p=0.003). Animals with the standard diet showed higher average blood glucose values (1.78). Mean values dropped (1.23) in the group treated with hypocaloric diet and in all groups receiving hCG. Among the treated groups, the lowest 263 mean values (0.97) were found in those receiving intrarectal suspension A/B/C. 264 Significant differences were found between the Control group with standard diet, groups 265 receiving Injectable A/B (1.11, p=0.019), and groups that received the Intrarectal 266 suspension A/B/C (p<0.001).

267 Weight assessment

268 Figure 3 shows modifications in the mean weight of the seven groups.

269 **Treatment effect**

270 Significant differences were found between the groups regarding weight modifications 271 (F=13,254, p < 0.001). The average percentage variation for the standard diet group was 272 0.4% (CI 95%; 8.8, 9.6). Results for the group with the hypocaloric diet were -24.7% (CI 273 95%; 29.9, 19.4) and for hCG-treated groups they were -16.8% (CI 95%; -20.3, -13.3). 274 Differences were significant in all three comparisons: the Control group with standard diet vs. the hypocaloric diet group (p < 0,001); the Control group with standard diet vs. 275 276 hCG-treated groups (p < 0.001); and the Control group with hypocaloric diet vs. hCG-277 treated groups (p < 0.001).

278 Dose effect

To assess the effect of the administered dose, groups were matched as follows: the Control group with standard diet, the Control group with hypocaloric diet, the groups with Injectable A/Intrarectal Suspension A, Injectable B/ Intrarectal Suspension C, and Intrarectal Suspension B. Significant differences were observed in weight percent change among groups between day 39 (baseline; before treatment, after cafeteria diet) and day 82 (Brown-Forsythe=10,394, p=0 < 0.001). Significant differences were also observed when comparing the Control group under the standard diet (average percentage variation 0.4; CI 95%; 8.8, 9.6) vs. the Control group with the hypocaloric diet (-24.7, CI 95% -29.9, -19.4) (p<0.001); vs. the Injectable A/Intrarectal Suspension A group (-18.1, CI 95% -25.1, -11.2) (p=0,001); and vs. the Injectable B / Intrarectal Suspension C group (-18.3, CI 95% -23.0, -13.7) (p=0,001). There was also a significant difference between the Control group with hypocaloric diet and the Intrarectal suspension B group (-8.7, CI 95%;-16.7, -0.6) (p=0.037).

292 Formulation effect

To assess the effect of the administered formulation, groups were analyzed as follows: 293 the Control group with standard diet, the Control group with hypocaloric diet, and the 294 Injectable A/Intrarectal suspension A/ Intrarectal suspension B, Injectable B/ Intrarectal 295 suspension C groups. Significant differences in average weight percentage variations 296 were observed between day 39 (baseline) and day 82 between the groups (Brown-297 298 Forsythe=11.201; 0.4-8.8, 9.6 p=0<0.001). Significant differences appeared when comparing the Control group with the standard diet (average percentage variation 0.4; CI 299 95% CI; -8.8, 9.6) vs. the Control group with hypocaloric diet (-24.7, CI 95%; -29.9, -300 301 19.4) (p < 0.001); vs. the Injectable A/Intrarectal suspension A/Intrarectal suspension B 302 group (-15.6, CI 95%; -21.2, -10.0) (p=0.004); and vs. the Injectable B/Intrarectal 303 suspension C (-18.3, CI 95% -23.0, -13.7) (*p*=0,001) group.

304 Histopathology

- 305 Significant morphological changes are summarized in Tables 1, 2 and 3.
- 306

307 DISCUSSION

308 Leptin plays a key role in the regulation of energy metabolism. In disorders such as 309 overweight and obesity, it is often elevated in plasma, suggesting that resistance to its action results in an impairment of the regulation of adipose tissue metabolism. Weight 310 311 gain also determines the presence of hyperglycaemia, a metabolic situation that clearly aggravates the underlying pathology (obesity). In this study, it was possible to observe 312 relevant differences about the effects of leptins. While the Control group with the 313 standard diet started the study with significantly lower mean values, the achieved 314 reduction was significantly less. Significant reductions in leptins were observed in the 315 Control group with hypocaloric diet and in the Injectable A and B groups. At the end of 316 the study, leptin results continued to be significantly different among some groups. The 317 Control group with the standard diet showed higher average values, while the Intrarectal 318 319 suspension B and C groups showed the lowest values.

In addition, significant differences were also observed in mean blood glucose results. The Control group with the standard diet achieved the highest average values; higher than those of the groups treated with intrarectal suspension A or B. The Control group with the standard diet showed mean leptin and blood glucose values significantly higher than the groups treated with hCG. Moreover, no significant differences were found between the values of the Control group that received a standard diet and the Control group with the hypocaloric diet.

Adiponectins and fatty Acids are not very sensitive to treatment when evaluating different doses and formulations. However, it was observed that, in relation to adiponectin, its values were elevated in animals receiving the hypocaloric diet, and even more so in the groups treated with hCG. Leptin and glucose levels were sensitive to 331 treatment. Leptin levels were significantly higher in the Control group, were decreased in 332 the hypocaloric diet group, and even more decreased in the animals that received hCG. When comparing analysis per dose, the group treated with intrarectal suspension B 333 334 showed the lowest values: the Injectable A/Intrarectal suspension A/Intrarectal suspension B groups showed the lowest levels in the analysis of the formulation, and the 335 Intrarectal suspension A/B/C groups showed the lowest levels in the analysis of the 336 pharmaceutical form. It is emphasized that no significant differences were observed 337 between the groups that did not receive hCG. A similar effect was observed regarding 338 glycemia. Treated groups showed significantly lower mean values in animals treated with 339 Intrarectal suspension B (per dose analysis), in the animals treated with Injectable 340 A/Intrarectal suspension A/Intrarectal suspension B (in the analysis of formulation), and 341 342 in the animals treated with Intrarectal Suspension A/B/C (in the analysis of pharmaceutical form). 343

These results demonstrate the activity of hCG (both urinary and recombinant) on 344 glycemia and leptins levels in different formulations, but especially when administered 345 intrarectal. Similarly to human studies performed by one of the authors (DOB), this 346 activity did not correlate with a greater weight loss when compared to a population 347 submitted to a standard hypocaloric diet. This result could either be attributed to the small 348 number of animals in each group or it may also indicate a possible hCG effect on body 349 composition, thereby favouring an increase in the lean mass component without 350 modifying the total body weight. In addition, no significant adverse clinical effects were 351 observed with the suprapharmacological doses administered (up to 400 times the dose/kg 352 353 of body weight administered in humans).

These findings confirm the results from former studies in humans that show that weight loss under hCG is no different when compared to placebo-treated individuals. However, according to the authors, this is the first report that shows that hCG has a definite action on leptins and blood sugar metabolism.

358 ACKNOWLEDGEMENTS

The BIO Fucal S.A. Center. Buenos Aires, Argentina. A laboratory specialized in biological assays. Sergio Ariel Vaney PhD, for his assistance in the preparation of hCG formulations. Nutritionist Mariela Carambia for her cooperation in the study and design of the cafeteria diet. Robert Gorman assisted us in manuscript editing.

363

364 **CONFLICT OF INTERST**

Note: This investigation was entirely funded by the lead investigator. The author applied

366 for a patent on the extragonadal use of hCG.

368 REFERENCES

1 Carne S. The action of chorionic gonadotropin in the obese. *Lancet* 1961; 11: 12821284.

- 2 Asher WL. Harper HW. Effect of human chorionic gonadotropin on weight loss,
- hunger and feeling of well-being. *Am J Nutr* 1973; 26: 211-218.
- 373 3 Simeons ATW. Pounds and Inches: a new approach to obesity. Private printing. 1974.
- 4 Bosch B, Venter I, Stewart RI, Bertram SR. Human chorionic gonadotropin and weight
- 375 loss. A double-blind, placebo-controlled trial. *S Afr Med J* 1990; 17; 77(4): 185-189.
- 5 Hutton JH, Creticos AP. Human chorionic gonadotropin (hCG) in treatment of obesity. *IMJ III Med J* 1967; 132(5): 693-695.
- 6 Maudlin RK. Gonadotropins in obesity? *Am Fam Physician* 1973; 8(4): 202-203.
- 7 NIH (National Institutes of Health, USA). Consensus panel: Health implications of
 obesity. *Ann Inter Med* 1985; 103: 147-151.
- 381 8 Perelberg H. Chorionic gonadotropin and obesity. *Med J Austr* 1977; 64(2): 68-69.
- 382 9 Vogt T, Belluscio D. Controversies in Plastic Surgery: Suction-Assisted lipectomy
- 383 (SAL) and the hCG (Human Chorionic Gonadotropin) Protocol for Obesity Treatment.
- *Aesth Plast Surg* 1987; 11: 131-156.

- 10 Belluscio D, Ripamonte L. El uso de la Gonadotrofina Coriónica Humana (hCG) por
 vía oral para el tratamiento de la obesidad: Estudio a doble ciego. *Rev Inst Med Sucre*1999; LXIV(115) : 14-21.
- 11 Belluscio D, Ripamonte L. Utility of an oral presentation of hCG for the Management
- 389 of Obesity. A double bind study. <u>http://hcgobesity.org/hcg.htm</u>
- 12 Paracchini V, Pedotti P, Taioli E. Genetics of Leptin and Obesity: A HuGE Review.
- *Am J Epidemiol* 2005; 162:101-114.
- 392 13 Simón E, Del Barrio AS. Leptina y obesidad. *Anales Sis San Navarra* 2002; 25(Supl.
 393 1): 53-64.
- 14 Hennessey J. Leptin as a fat orchestrator. *Reviews in Undergraduate Research* 2003;
 Vol. 2: 12-18.
- 15 Geldszus R, Mayr B, Horn R, Geisthovel F, von zur Muhlen A, Brabant G. Serum
 leptin and weight reduction in female obesity. *European Journal of Endocrinology* 1996;
 135(6): 659-662.
- 16 Christos S, Mantzoros. The Role of Leptin in Human Obesity and Disease: A Review
 of Current Evidence. *Annals of Internal Medicine* 1999; 130(8): 671-680.
- 401 17 Jeanrenaud B, Rohner-Jeanrenaud F. Effects of neuropeptides and leptin on nutrient
- 402 partitioning: Dysregulations in Obesity. *Annual Review of Medicine* 2001; 52: 339-351.
- 403 18 Thorkild Ia Sorensen, Echwald SM, Holm JC. BMJ 1996; 313: 953.

- 404 19 Fariñas Rodríguez L, Meléndez Minobis M, Martínez Z, Travieso Y, Posada A,
 405 Dujarric M. Control de la alimentación y leptina. *Rev Cubana Invest Biomed* 2005;
 406 24(1): 47-53.
- 407 20 Burguera B, Couce ME, Curran GL, Jensen MD, Lloyd RV, Cleary MP, Poduslo JF.

408 Obesity Is Associated With a Decreased Leptin Transport Across the Blood-Brain Barrier

409 in Rats. *Diabetes* 2000; 49: 1219-1223.

410 21 Montserrat Barbany Cahiz. Déficit de leptina y obesidad. *Rev Esp Obes* 2003;Vol I
411 Núm.1: 47-48.

22 Echwald SM, Clausen JO, Hansen T, Urhammer SA, Hansen L, Dinesen B, BorchJohnsen K, Pedersen O. Analysis of the relationship between fasting serum leptin levels
and estimates of beta-cell function and insulin sensitivity in a population sample of 380
healthy young Caucasians. *European Journal of Endocrinology* 1999, vol. 140, no2, pp.
180-185

417 23 Considine RV, Sinha MK, Heiman ML, Kriauciunas A, Stephens TW, Nyce MR, et

al. Serum immunoreactive-leptin concentrations in normal-weight and obese humans. N *Eng J Med* 1996; 334(5): 292-295.

24 Schwartz MW, Prigeon RL, Kahn SE, Nicolson M, Moore J, Morawiecki A, et al.
Evidence that plasma leptin and insulin levels are associated with body adiposity via
different mechanisms. *Diabetes Care* 1997; 20(9): 1476-1481.

423	25 Krempler F, Hell E, Winkler C, Breban D, Patsch W. Plasma Leptin Levels :
424	Interaction of Obesity With a Common Variant of Insulin Receptor Substrate-1.
425	Arterioscler Thromb Vasc Biol. 1998;18: 1686-1690.

- 426 26 Musri MM, Gomis R, Casamitjana R, Enrich Bastùs C. Expresion de Adiponectina y
- 427 sus receptores en tejido adiposo. Regulación epigenetica en la adipogenesis. Tesis
 428 Facultad de Medicina, Universidad de Barcelona 2003-2004.
- 27 Musri MM, Gomis R, Casamitjana R, Enrich Bastùs C. Expresion de Adiponectina y
 sus receptores en tejido adiposo. Regulación epigenetica en la adipogenesis. Tesis
 Facultad de Medicina, Universidad de Barcelona 2003-2004.
- 28 Mandenoff A, Lenoir T, Apfelbaum M. Tardy occurrence of adipocyte hyperplasia in
 cafeteria-fed rat. *Am J Physiol* 1982; 242:R349–R351.

TABLES:

435 <u>**Table 1**</u>. Adverse events in brain histopathology per group/sex

Brain Histopathology	Group/sex
Vascular congestion in meninges and parenchyma.	Group 4: 1 female
	Group 6: 1 female
Vascular congestion and erythrocyte extravasation in	Group 5: 1 female
meninges.	
Focal points of RBC extravasation in parenchyma	Group 0: 1 female
Marked vascular congestion in meninges	Group 5: 1 female
	Group 6: 1 female

437 <u>**Table 2.**</u> Adverse events in testicular histopathology per group.

Testicular	Groups							
histopathology.	0	1	2	3	4	5	6	
Mild autolysis	2	2	3	2				
Moderate autolysis	1		1	3	3	3	1	

Ovary histopathology.	Groups						
	0	1	2	3	4	5	6
CL (Corpus Luteum)							1
Yellowish-brown pigmento							
focal points.			1				
Follicles in different maturation							
stages	2	1	3	2	3	5	2
Corpus Luteum in different							
maturation stages	1						
Interstitial cell hyperplasia.	2						
Interstitial cells hyperplasia and							
hypertrophy.	1	1	3	2	3	3	3
Interstitial cells mild							
hyperplasia.		2					
Luteomas	1	1	3	2	3	3	3
Pigment in CL				1	1		
Cysts			2	2	2		

439 <u>**Table 3**</u>. Adverse events in ovaries histopathology per group.

- 441 FIGURES
- **Figures 1(A—D).** Mean baseline determinations per group
- **Figure 1A.** Mean leptin baseline levels per group




Figure 1A: Mean leptin baseline levels per group

Figure 1B. Mean blood glucose (glycemia) baseline levels per group






Figure 1C. Mean adiponectin baseline levels per group






Fig 1 C: Mean adiponectin baseline levels per group

Figure 1D. Mean fatty acids baseline levels per group





- **Figures 2(A—D).** Mean final determinations per group
- **Figure 2A.** Mean leptin final levels per group







Figure 2B. Mean blood glucose (glycemia) final levels per group








Figure 2D. Mean fatty acids final levels per group




Figure 2 D: Mean final fatty acids levels per group




Figure 3: Body weight evolution per group

Figure 1A: Mean leptin baseline levels per group




Figure 1 B: Mean blood glucose (glycemia) baseline levels per group




Fig 1 C: Mean adiponectin baseline levels per group




Figure 1 D: Mean fatty acids baseline levels per group




Figure 2 A: Mean final leptin levels per group




Figure 2B: Mean final blood glucose levels per group




Figure 2C: Mean final adiponectin levels per group




Figure 2 D: Mean final fatty acids levels per group

